Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

82 results about "Myostatin" patented technology

Myostatin (also known as growth differentiation factor 8, abbreviated GDF-8) is a myokine, a protein produced and released by myocytes that acts on muscle cells' autocrine function to inhibit myogenesis: muscle cell growth and differentiation. In humans it is encoded by the MSTN gene. Myostatin is a secreted growth differentiation factor that is a member of the TGF beta protein family.

Selective and potent inhibitors of myostatin activation

The present disclosure relates to antibodies and antigen-binding fragments that specifically bind to a promyostatin / latent myostatin and uses thereof.
Owner:SCHOLAR ROCK INC

Methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteins

The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin / activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
Owner:ALIVEGEN INC

Application of serum MSTN (myostatin) as marker in preparation of metabolism-related steatohepatitis diagnosis product

The invention discloses application of serum MSTN (myostatin) as a marker in preparation of a metabolism-related steatohepatitis diagnosis product, and belongs to the technical field of biomedical detection. The biomarker for noninvasive diagnosis of the metabolism-related steatohepatitis is serum myosostatin MSTN, and the biomarker can be used as a detection target for preparing a noninvasive diagnosis product of the metabolism-related steatohepatitis. As an independent biomarker, the MSTN is higher in diagnosis efficiency in AST normal patients; the MSTN and the ALT or the AST are jointly applied, so that the specificity and the positive predictive value (PPV) of single use of the ALT or the AST can be improved, the misdiagnosis rate of the ALT or the AST can be reduced, non-MASH patients can be more accurately excluded, and unnecessary, invasive or expensive subsequent examinations are reduced.
Owner:NANJING DRUM TOWER HOSPITAL

Administration of fibronectin-based scaffold domain proteins to treat overweight, obesity and related health conditions

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).
Owner:BIOHAVEN THERAPEUTICS LTD

A skin external preparation exhibiting an effect of inhibiting muscle loss or promoting muscle generation by an extracellular vesicle derived from skin

The present application relates to a composition capable of increasing the level of microRNA-26a in extracellular vesicles and the use of the composition, which can increase the level of microRNA-26a (miRNA-26a) in exosomes secreted from cells, and the exosomes can not only reduce the expression of biomarkers involved in muscle reduction, i.e. muscle ring finger protein 1 (MURF 1), human atrogin-1 (atrogin-1) and myostatin (myostatin), but also increase the expression of myogenic regulatory factor (myoD) involved in muscle generation. Therefore, the composition capable of increasing the level of microRNA-26a in extracellular vesicles can be used as an inhibitor of muscle loss and a promoter of muscle generation.
Owner:EX HEALTHCARE INC

Pharmaceutical composition for prevention or treatment of sarcopenia in companion animals

PCT designated stage expiredWO2025041931A1Tetrapeptide ingredientsMuscular disorderMyostatinMuscle loss
The present invention relates to a pharmaceutical composition for the prevention or treatment of sarcopenia in companion animals. The pharmaceutical composition inhibits an increase in the production and mRNA expression of myostatin protein, which directly affects muscle loss and reduced muscle strength, and thus can exhibit the effect of more fundamentally preventing or treating sarcopenia in companion animals.
Owner:MYOPET INC

Agent for reducing blood myostatin level

A novel preventive and / or therapeutic agent useful in the prevention and / or treatment of a disease whose symptom is alleviated or improved by the inhibition of myostatin. The present invention relates to an agent for preventing and / or treating a disease whose symptom is alleviated or improved by the inhibition of myostatin, the agent including a therapeutically effective dose of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.
Owner:KOWA CO LTD

Myostatin-selective inhibitors for treating metabolic disorders

Disclosed herein are therapeutic uses of myostatin-selective inhibitors, such as myostatin-selective inhibitors, for treating metabolic disorders, such as obesity. Data presented herein support the notion that selectively targeting myostatin without inhibiting Activin A can achieve equivalent or enhanced efficacy when used in conjunction with a GLP-1 receptor agonist in improving body composition, as compared to broadly antagonizing the ActRII pathway in conjunction with a GLP-1 receptor agonist. Administration of a myostatin-selective inhibitor can prolong the effect of semaglutide on fat mass loss. Moreover, administration of a myostatin-selective inhibitor can elicit positive effects on bone in all parameters evaluated, indicating that diet- or inflammation-induced bone atrophy may be prevented by selective inhibition of the myostatin pathway.
Owner:SCHOLAR ROCK INC

Medium additive composition for culturing cultured meat, comprising laxogenin or 5-alpha hydroxy laxogenin

The present invention relates to: a cultured meat medium additive and a cultured meat medium composition that can induce muscle growth by differentiating muscle stem cells into muscle cells and inhibiting the expression of myostatin, which inhibits muscle growth; and a method for preparing cultured meat by using same. Specifically, the cultured meat medium additive and the cultured meat medium composition comprise laxogenin and 5-alpha hydroxy laxogenin.
Owner:RES COOPERATION FOUND OF YEUNGNAM UNIV

Pharmaceutical composition for preventing or treating muscular dystrophy comprising zaltoprofen as active ingredient

PCT designated stage expiredWO2025028968A1Muscular disorderNeuromuscular disorderMyostatinMuscle loss
The present invention provides a composition for preventing or treating muscular dystrophy, the composition comprising Zaltoprofen as an active ingredient. The composition according to the present invention increases the expression of utrophin, reduces the expression of myostatin, MAFbx, and MuRF1, and can inhibit muscle loss, increase muscle, and improve muscle function by inducing muscle differentiation and increasing the diameter of myotubes. Thus, the composition is expected to be used in various ways as medicines, quasi-medicines, fragrance materials, functional biomaterials, and functional food materials for alleviating, preventing, or treating muscular dystrophy.
Owner:KOREA UNIV RES & BUSINESS FOUND +1

Methods of using activin a and myostatin signaling inhibitors

PCT designated stageWO2025174995A1Splicing alterationNervous disorderMyostatinAntigen
The invention features methods of treating a subject having Duchenne muscular dystrophy by administering an activin A and myostatin signaling inhibitor in combination with a dystrophin exon skipping therapy. The activin A and myostatin signaling inhibitor may be an activin A antibody or an antigen binding fragment thereof and an anti-myostatin protein (e.g., a myostatin antibody or an antigen binding fragment thereof or an anti-myostatin adnectin recombinant protein), an ActRII antibody or an antigen binding fragment thereof, or an extracellular ActRII ligand trap.
Owner:KEROS THERAPEUTICS INC

Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
Owner:CHUGAI PHARMA CO LTD

Double-stranded sirna analog for inhibiting MSTN expression, preparation method therefor, and use thereof

Provided are a double-stranded siRNA analog for inhibiting myostatin (MSTN) expression, a preparation method therefor, and use thereof. The double-stranded siRNA analog can inhibit MSTN expression and be used for preventing and / or treating MSTN-related diseases and disorders, such as myoatrophy.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Method relating to myostatin pathway inhibition

The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and / or activin type II receptor (ActRII) and / or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and / or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and / or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and / or ActRII receptor in the at least one biopsy sample is higher than a threshold level and / or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.
Owner:UCL BUSINESS LTD

Methods for treating metabolic diseases by inhibiting myostatin activation

To provide a composition for treating or preventing metabolic diseases.SOLUTION: The present invention provides a composition comprising an antibody, or antigen-binding fragment thereof that specifically binds pro / latent-myostatin and blocks release of mature myostatin, for use as a medicament in treatment or prevention of a metabolic disease in a human subject, comprising steps of: selecting a human subject suffering from or at risk of developing a metabolic disease; and administering to the human subject the composition comprising an effective amount of the antibody, or antigen-binding fragment thereof.SELECTED DRAWING: None
Owner:SCHOLAR ROCK INC

A sodium alginate / calcium beta-hydroxy-beta-methylbutyrate instant gelation powder with dual functions of fat reduction and muscle gain and application thereof

PendingCN122350341AMyostatinUronic acid
This invention discloses an instant gelling powder of sodium alginate / calcium β-hydroxy-β-methylbutyrate with dual functions of fat reduction and muscle gain, and its application, belonging to the field of functional food or pharmaceutical preparation technology. The powder of this invention is prepared by dry mixing sodium alginate and CaHMB at a weight ratio of 5~10:1~5, preferably 7:3, wherein the guluronic acid content of sodium alginate is ≥50%. In use, 1g of powder is added to 20~40mL of water at 60~100°C, and stirred to form a hydrogel. After oral administration, the powder rapidly forms a gel in the stomach, producing a feeling of fullness, and simultaneously achieves fat reduction, muscle gain, and metabolic regulation functions by regulating myostatin expression. This invention overcomes the limitation of existing weight management products with only one function, innovatively integrating the three major effects of instant satiety, fat reduction, and muscle gain. The preparation process is simple and environmentally friendly, requiring no added chemical excipients, and has significant technological advancement and market application value.
Owner:DALIAN POLYTECHNIC UNIVERSITY

A composition for improving muscle attenuation and promoting myogenic differentiation, and products and uses thereof

PendingCN123024091ABiotechnologyMyostatin
The present application relates to a composition for improving muscle attenuation and promoting myogenic differentiation and products and applications thereof. The composition comprises epicatechin, sulforaphane and astragalus polysaccharide, and the mass ratio of the three is 1:1:100. The composition can be prepared into various product forms such as chocolate, coffee, health tea, etc. Through combined intervention, the composition can significantly improve muscle mass, muscle strength and muscle function, increase lean meat content, and reduce the gene expression level of myostatin in muscle without affecting body fat metabolism. The composition has both functionality and nutrition, and the synergistic improvement effect is significantly better than that of two-by-two combination and single component intervention. The composition has broad application prospects in improving muscle attenuation, promoting myogenic differentiation and improving muscle health status.
Owner:CHINA AGRI UNIV

Pharmaceutical composition for preventing or treating muscle diseases

The present disclosure relates to a pharmaceutical composition for preventing or treating muscle diseases. Particularly, an elderberry extract or a monosaccharide- and amino acid-coupled compound, according to the present disclosure exhibits the effects of inhibiting muscle cell apoptosis, inhibiting the expression of inflammatory cytokines, promoting the secretion of testosterone, inhibiting the expression of muscle atrophy markers and myostatin and causing muscle to recover in sarcopenia animal models, and thus can be effectively used in the treatment of muscle diseases.
Owner:KOSA BIO CO LTD

Method for constructing mouse model for rapid degradation of MSTN protein

PendingUS20260198467A1FKBP1AMyostatin
A method for constructing a mouse model for rapid degradation of Myostatin (MSTN) protein is provided. The method includes: inserting sequentially a 5′ homologous arm, 3 X (Glu-Ala-Ala-Ala-Lys) (3xEAAAK), an FK506-binding protein (FKBP1A) gene synonymous mutation sequence, 3xEAAAK, a red fluorescent protein monomeric Cherry (mCherry) sequence and a 3′ homologous arm into a Donor vector backbone to obtain a Donor recombinant vector; designing a Guide Ribonucleic Acid (gRNA) based on a third exon of the Mstn gene; mixing the gRNA, CRISPR-associated protein 9 (Cas9) protein, and the Donor recombinant vector and co-injecting a mixture of the above into mouse fertilized eggs, culturing the fertilized eggs in vitro and transplanting to obtain the F0 generation mice; and hybridizing the F0 generation mice with wild-type mice, or further breeding hybridized offspring to obtain a knock-in mouse model.
Owner:NORTHWEST A & F UNIV

Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments

The present invention relates to a combination therapy of an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins for the treatment of muscle loss related to obesity. The microorganism may be formulated to include pharmaceutically viable excipients, such as antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, or vehicles.
Owner:NORTHSTRIVE BIOSCIENCES INC

Methods of using activin receptor type ii signaling inhibitors

PCT designated stageWO2025184284A1Antibody mimetics/scaffoldsPeptide/protein ingredientsActivin Receptors Type IIBone marrow fibrosis
The invention features methods of treating a subject having myelofibrosis by co-administering an activin receptor type II (ActRII) signaling inhibitor and a myelofibrosis therapy. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, an ActRII ligand trap, or an anti-myostatin adnectin recombinant protein.
Owner:KEROS THERAPEUTICS INC

Stabilized receptor polypeptides and uses thereof

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
Owner:AMGEN INC

Pharmaceutical composition for preventing or treating muscle diseases

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases. Specifically, the elderberry extract or monosaccharide and amino acid combined compound disclosed by the invention inhibits apoptosis of muscle cells, inhibits expression of inflammatory cytokines, promotes secretion of testosterone and inhibits expression of amyotrophy marker protein and myogenesis inhibition protein, and shows an effect of recovering muscle in a sarcopenia animal model; therefore, the device can be effectively used in the treatment of muscle diseases.
Owner:KOSA BIO CO LTD